United States Biotechnology & Medical Research

Hemab Therapeutics Holdings Inc (COAG)

RA Capital Management, L.P. executed multiple purchase transactions for Hemab Therapeutics Holdings Inc. shares between May 4 and June 16, 2026. These acquisitions represent the most recent insider trading activity recorded for the firm. No further buying or selling occurred within the last three months.
Ticker: COAG Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Hemab Therapeutics Holdings Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
24.83
Quantity 53,407 +0.9%
Value US$1,326,096
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
23.77
Quantity 14,611 +0.2%
Value US$347,303
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
25.00
Quantity 10,268 +0.2%
Value US$256,700
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
24.59
Quantity 87,143 +1.4%
Value US$2,142,846
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 133,750 +60.5%
Value US$2,407,500
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 2,541,250 +70.4%
Value US$45,742,500
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-17 2026-06-16 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
48,027 +32.7%
138.71
US$4,609,094 		48,027 +32.7% 138.71 US$4,609,094
2026-06-17 2026-06-15 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
84,113 -40.0%
435.29
US$1,865,953 		84,113 -40.0% 435.29 US$1,865,953
2026-05-21 2026-05-20 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
21,161 +24.4%
387.80
US$1,637,037 		21,161 +24.4% 387.80 US$1,637,037
2026-05-21 2026-05-19 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
3,802 +0.1%
24.97
US$94,936 		3,802 +0.1% 24.97 US$94,936
2026-05-14 2026-05-12 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
6,387 +0.1%
24.90
US$159,036 		6,387 +0.1% 24.90 US$159,036
2026-05-11 2026-05-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
25,720 +0.4%
25.00
US$643,000 		25,720 +0.4% 25.00 US$643,000
2026-05-11 2026-05-11 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
14,149 +0.2%
24.47
US$346,226 		14,149 +0.2% 24.47 US$346,226
2026-05-11 2026-05-08 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
1,483 +0.0%
24.98
US$37,045 		1,483 +0.0% 24.98 US$37,045
2026-05-11 2026-05-07 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
1,985 +0.0%
24.95
US$49,526 		1,985 +0.0% 24.95 US$49,526
2026-05-11 2026-05-07 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Large shareholder
7,921 +0.1%
24.34
US$192,797 		7,921 +0.1% 24.34 US$192,797
2026-05-06 2026-05-06 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
53,407 +0.9%
24.83
US$1,326,096 		53,407 +0.9% 24.83 US$1,326,096
2026-05-06 2026-05-06 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
14,611 +0.2%
23.77
US$347,303 		14,611 +0.2% 23.77 US$347,303
2026-05-06 2026-05-05 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
10,268 +0.2%
25.00
US$256,700 		10,268 +0.2% 25.00 US$256,700
2026-05-06 2026-05-05 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
87,143 +1.4%
24.59
US$2,142,846 		87,143 +1.4% 24.59 US$2,142,846
2026-05-06 2026-05-04 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
133,750 +60.5%
18.00
US$2,407,500 		133,750 +60.5% 18.00 US$2,407,500
2026-05-06 2026-05-04 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
2,541,250 +70.4%
18.00
US$45,742,500 		2,541,250 +70.4% 18.00 US$45,742,500
Explore more

More insider trading research around Hemab Therapeutics Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America